Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab.

Abstract

A 52 year -old female developed a histologically aggressive, Epstein-Barr virus positive, lymphoproliferative disorder involving the brain and liver 4 months following a combined kidney/pancreas transplant. Following a brief trial of reduced immunosuppression, she was treated with rituximab. Despite subsequent re-intensification of immunosuppression, the lesions showed continued regression with almost complete disappearance by 5 months. Rituximab appears to be a safe, effective treatment for post transplant lymphoproliferative disorder.

• Authors: M E O'Dwyer, T Launder, J M Rabkin, C R Nichols
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 39 Issue 3-4 Pg. 411-9 (Oct 2000) ISSN: 1042-8194 [Print] United States
• PMID: 11342323 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents
• Rituximab

Topics

• Antibodies, Monoclonal (administration & dosage)
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents (administration & dosage)
• Brain Neoplasms (drug therapy, etiology, virology)
• Disease-Free Survival
• Female
• Herpesvirus 4, Human
• Humans
• Kidney Transplantation (adverse effects)
• Liver Neoplasms (drug therapy, etiology, virology)
• Lymphoproliferative Disorders (drug therapy, etiology, virology)
• Middle Aged
• Pancreas Transplantation (adverse effects)
• Rituximab